IMAGE: THE TWO THERAPIES DEMONSTRATED SIMILAR MID-TERM SAFETY AND EFFICACY, WHILE EACH CELL THERAPY HAD ITS UNIQUE ADVANTAGES AND ARE RECOMMENDED FOR CERTAIN CONDITIONS: FOR EXAMPLE, PBMNCS FOR PATIENTS WITH 2… view more CREDIT: ALPHAMED PRESS
https://www.eurekalert.org/pub_releases/2021-01/ap-mct010421.php
